HIV, HBV, HCV Virology. Anna Maria Geretti Institute of Infection & Global Health University of Liverpool
|
|
- John Jeffry Allen
- 5 years ago
- Views:
Transcription
1 HIV, HBV, HCV Virology Anna Maria Geretti Institute of Infection & Global Health University of Liverpool
2 HIV HBV HCV Many similarities Several fundamental differences
3 High-level replication: HIV 10 10, HBV 10 11, HCV particles/day Rapid clearance of newly produced virus High mutation rate quasispecies Some mutations detrimental, some allow escape Quasispecies Escape rapid turnover rapid adaptation Fitness
4 Antiviral resistance Drug resistant variants are produced spontaneously during virus replication Single, double, and even triple mutants emerge daily in untreated patients persistence as replicating variants directly related to the fitness cost of the mutations Tolerance for mutations is HCV > HIV > HBV
5 HIV HCV HBV
6 Emergence & evolution of HIV drug resistance Single mutant Double mutant Triple mutant
7 Virus without resistance mutations Virus with resistance mutations Virus with resistance and compensatory mutations
8 HCV genetic variability NS3: 42% of amino acid conserved among all genotypes NS5A: 46% of amino acid conserved among all genotypes NS5B: 55% of amino acid conserved among all genotypes
9 HIV RNA virus Chronic infection Without treatment, most people develop AIDS and die within ~10 years (7.5 to 11.6) 1,2 Non-AIDS HIV-related disease Latent reservoir as integrated provirus Antiviral therapy controls but does not eradicate HIV Life-long therapy required to suppress virus replication PrEP and PEP 1. Todd AIDS 2007; 2. Laskey Nature Rev Microbiol 2014
10 The HIV virology timeline HIV-1 isolated HIV replicates at high levels throughout the infection Highly active antiretroviral therapy Plasma HIV RNA ( viral load ) suppression as goal of therapy HIV eradication research HIV-1 genome sequenced HIV replication drives immune compromise HIV replication causes disease through immune activation & inflammation
11 Primary HIV infection Encompasses the first 6 months after infection Presents symptomatically in 23-92% of individuals 1-14 Usually clinically mild, temporary and self-limited Characterised by high levels of virus replication 15 High risk of onward transmission Can contribute to >50% of all transmissions within focussed epidemics 16 Exacerbated by concomitant acquisition of STIs 17 Viral dissemination and establishment of long-lived viral reservoir occurs rapidly after HIV acquisition STIs = Sexually Transmitted Infections 1. Cooper et al. Lancet 1985; 2. Fox et al. AIDS 1987; 3. Quinn TC. JAMA 1997; 4. Tindall et al. Arch Intern Med 1988; 5. Gaines et al. BMJ 1988; 6. Kinloch-de Loes et al. Clin Infect Dis 1993; 7. Dorrucci et al. AIDS 1995; 8. Schacker et al. Ann Intern Med 1996; 9. Bollinger et al. JAMA 1997; 10. Hofer et al. J Acquir Immune Defic Syndr 2000; 11. Lavreys et al. Clin Infect Dis 2000; 12. Vanhems et al. J Acquir Immune Defic Syndr 2002; 13. Daar et al. Curr Opin HIV AIDS 2008; 14. Braun et al. Clin Infect Dis 2015; 15. Quinn et al. N Engl J Med 2000; 16. Phillips et al. AIDS 2015; 17.Ward et al. Curr Opin HIV AIDS 2010; 18. Lodi et al. Clin Infect Dis 2011; 19. Katlama et al. Lancet 2013; 20. Kulpa et al. J Virus Erad 2015; 21. Ananworanich et al. J Virus Erad 2016
12 Attachment Fusion Release of RNA Reverse transcription Integration Transcription Assembly HIV replication Maturation & budding
13 Mechanisms of HIV genetic evolution 1. Errors by viral reverse transcriptase ~1 mis-incorporation per genome round 2. Errors by cellular RNA polymerase II 3. APOBEC-driven G A hypermutation Deamination of cytosine residues in nascent DNA 4. Recombination between HIV strains
14 HIV replication resumes if therapy is stopped Effective therapy 1000 HIV RNA in plasma 10 Dec-04 Jun-05 Dec-05 Jun-06 Dec-06 Jun-07 Dec-07 Jun-08 Dec-08 Jun-09 Dec-09 Jun-10 Antiretroviral therapy cannot achieve HIV eradication After stopping therapy HIV replication resumes to pre-treatment levels A few exceptions exist
15 HIV DNA forms Host cell 2-LTRc Nucleus HIV RNA Linear HIV DNA 1-LTRc Proviral DNA Integration HIV RNA Host DNA
16 Effect of fully suppressive ART on markers of HIV persistence scd14 CD8 + HLA-DR + CD8 + CD38 + CD4 + CD69 + CD4 + CD38 + CD4 + CD26 + CD4 count Integrated HIV-1 DNA Total HIV-1 DNA 2-LTRc DNA Residual plasma HIV-1 RNA LESS MORE p=0.19 p=0.17 p=0.01 p=0.22 p=0.01 p=0.69 p=0.28 p=0.60 p=0.01 p= p=0.05 Mean difference Mean Change per 10 by years duration of of suppressive VLS<50 cps ART log-transformed variables Ruggiero. EBiomed 2015
17 Fusion inhibitors CCR5 antagonists Attachment Fusion Release of RNA RT inhibitors Integrase inhibitors Reverse transcription Integration Transcription Assembly Protease inhibitors Targets of therapy Maturation & budding
18 Maturation & budding Protease Polyprotein
19 HIV Reverse transcriptase/polymerase Two mechanisms of inhibition Competitive NRTIs Allosteric NNRTIs Wright et al. Biology 2012
20 Primer strand NRTI 5 DNA chain terminated 3 5 Template strand
21 Mechanisms of NRTI resistance M184V (3TC, FTC) T215Y (AZT, ABC, ddi, d4t, TDF)
22 Mechanisms of NRTI resistance M184V T215Y Antagonised by M184V
23 Replicative capacity ( fitness ) of integrase resistant mutants Hightower Antimicrob Agents Chemother 2011; Quashie J Virol 2012; Wainberg ISHEID Conference 2014
24 Codon usage at integrase position 140 in B vs. non-b subtypes GGT or GGC Glycine GGA or GGG subtype B AGT or AGC non-b subtypes Serine Doyle JAC 2015
25 HCV RNA virus Chronic infection ~75-80% Cirrhosis (41% over 30 years), hepatocellular carcinoma Extra-hepatic disease increasingly recognised 1,2 No stable or latent reservoir Simple life cycle Curable with antiviral therapy Cytoplasm Nucleus 1. Giordano JAMA 2007; 2. Lee JID 2012
26 HCV replication HCV enzymes provide good targets for drug development HCV Replicase HCV enzymes provide good targets for drug development HCV Replicase C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A Structural Protease NS5B RNA Polymerase Cleavage C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A Structural Protease NS5B RNA E2 Polymerase E1 NS2 P7 NS3 4A Protease NS4B NS5A NS5B Polymerase HCV replicase Replicated HCV RNA Cleavage C NS5B NS5B Polymerase HCV DrAG ResisSS 2012 v.1 9 Adapted from Kwong AD, et al. Curr Opin Pharmacol. 2008; 8(5): E1 E2 P7 NS2 NS3 4A Protease NS4B NS5A HCV replicase Replicated HCV RNA C NS5B Brett Nature 2005
27 Antiviral targets & drug classes Ledipasvir Daclatasvir Ombitasvir Elbasvir Velpatasvir NS5A Inhibitors NS3 Protease Inhibitors Telaprevir Boceprevir Simeprevir Paritaprevir/ritonavir Grazoprevir NS5B Polymerase Inhibitors Nucleoside/nucleotide analogues: Sofosbuvir Non-nucleoside analogues: Dasabuvir
28 Efficacy of antiviral therapy: Overview Gt 1/4 SMV PI + + SOF SOF 12wks SVR rates in patients without cirrhosis (NB: no head-to-head studies) SVR (%) Gt 1/4 DCV SOF + SOF DCV 12 wks Gt 1/4 SOF/LDV + 12 wks Gt 1/4 PI/r/NS5A PrOD +/- RBV + NS5B 12 wks +/- RBV 12 wks Gt 2 SOF + RBV 12 wks Gt 3 SOF DCV + + DCV SOF 12 wks SVR = Sustained Virological Response; Gt = Genotype; PI = protease Inhibitor (r = ritonavir); SOF = sofosbuvir; DCV = daclatasvir; LDV = ledipasvir; RBV = ribavirin Kwo. EASL 2015; Wyles. EASL 2015; Afdhal. NEJM 2014; Feld. NEJM 2014; Zeuzem. NEJM 2014; Gane. NEJM Nelson. Hepatology 2015
29 Risk of re-infection after SVR 1 Relapse of IDU predicts risk of re-infection 2 1. Hill. CROI 2015; 2. Midgard. J Hepatol 2016
30 Characteristics of current DAAs DAA Class Potency BL RAS TE RAS Agents NS3 Protease NS5B Polymerase NA NS5B Polymerase Non-NA +++ to to to +++ Relatively common Rare Highly common Rare to uncommon Simeprevir Paritaprevir Grazoprevir Sofosbuvir Common Highly common Dasabuvir NS5A ++++ Common Highly common BL = Baseline; TE = Treatment-Emergent; RAS = Resistance-Associated Substitutions NA = Nucleoside / Nucleotide Analogue; Non-NA = Non-Nucleoside Analogue Ledipasvir Daclatasvir Ombitasvir Elbasvir
31 HBV DNA virus Vaccine Chronic infection in >90% children, <5% adults Cirrhosis (~30%) Hepatocellular carcinoma (with/without cirrhosis) Extra-hepatic disease Persistence as cccdna, may integrate Several replicative states Antiviral therapy not always required, controls but does not eradicate HBV, probably life-long Antivirals work as PrEP
32 HBV replication
33 HBV drug targets Nucleoside and nucleotide analogues Lamivudine* Adefovir Entecavir* Telbivudine Tenofovir* Emtricitabine*
34 Incidence of HBV drug resistance Years 1-5; first-line therapy
35 Drug resistance with HIV, HBV, HCV Drug-resistant mutants emerge spontaneously during virus replication Tolerance for mutation is HCV > HIV > HBV Virus replication under drug pressure drives expansion of the mutants Natural evolution increasing resistance & fitness If therapy is stopped, drug susceptible virus tends to outgrow resistant mutants selected by therapy mutants persist as enriched minority species Mutants are archived in HIV DNA provirus and HBV cccdna No archive for HCV
36 The barrier to resistance is expression of multiple interacting factors Virus sequence Phenotypic effect of individual mutations No. of mutations required to reduce drug susceptibility Fitness cost of the mutation Ease of emergence of compensatory adjustments Drug potency Mode of interaction between drug and target Drug concentration Drug combination Antagonism or synergism between resistance pathways Viral load Host genetics Host immune function Reservoirs of replications Disease stage More than the sum of each drug in a regimen
37 Your turn Which of the following correctly describes HIV? 1. RNA virus, high replication during AIDS phase only 2. RNA virus, high replication, stable genetic make-up 3. RNA virus, high replication, rapid genetic evolution
38 Your turn Which of the following correctly describes HIV? 1. RNA virus, high replication during AIDS phase only 2. RNA virus, high replication, stable genetic make-up 3. RNA virus, high replication, rapid genetic evolution
39 Your turn Which of the following correctly describes HBV? 1. HBV polymerase lacks reverse transcriptase activity 2. The genomic structure favours rapid emergence of resistance 3. Resistance is less of a problem with 3 rd gen drugs
40 Your turn Which of the following correctly describes HBV? 1. HBV polymerase lacks reverse transcriptase activity 2. The genomic structure favours rapid emergence of resistance 3. Resistance is less of a problem with 3 rd gen drugs
41 Your turn Which of the following correctly describes HCV? 1. Resistance is created by suboptimal therapy 2. Resistance is selected by suboptimal therapy 3. Resistance is archived in the nucleus of hepatocytes
42 Your turn Which of the following correctly describes HCV? 1. Resistance is created by suboptimal therapy 2. Resistance is selected by suboptimal therapy 3. Resistance is archived in the nucleus of hepatocytes
43
44
45 HIV tropism defined by co-receptor use X4 D R5 CD4 CXCR4 CCR5 Naive CD4 cells Memory CD4 cells Macrophages Must be activated to memory phenotype to become target of R5 Esté Lancet 2007
Hepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationHBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD
HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More information5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHCV Drug Resistance: Regulatory Perspective
HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington,
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationHCV eradication with direct acting antivirals (DAAs)?
HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr HCV eradication with direct
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationSection 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationOvercoming barriers to access to hepatitis C treatment in a rapidly changing landscape
Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape HIV/AIDS Department and Global Hepatitis Programme Dr. Stefan Wiktor Outline Global Hepatitis Strategy New HCV treatment
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 5
National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationMassimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda
Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Innovative strategies in viral hepatitis : Hepatitis C: Interferon and/or Ribavirin free regimens 10th International Workshop on
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationDogma: HCV treatment for eradication. Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015
Dogma: HCV treatment for eradication Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015 Disclosures Some discussion of non-hc approved compounds Industry:
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationHepatitis B and Hepatitis C Virus in non-liver Transplant Recipients. Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London
Hepatitis B and Hepatitis C Virus in non-liver Transplant Recipients Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London Financial Disclosures Research Grants Merck, Gilead, Abbvie,
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationHCV/HIV Coinfection ANTON AND MARGARET FUISZ CHAIR IN MEDICINE. HIV and HCV Share Risk Factors PREVALENCE OF CO-INFECTION BY RISK FACTOR 60%
HCV/HIV Coinfection BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY HIV and HCV Share Risk Factors PREVALENCE
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationIntroduction to the Impact of Resistance in Hepatitis C
Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationClinical utility of NGS for the detection of HIV and HCV resistance
18 th Annual Resistance and Antiviral Therapy Meeting v Professor Janke Schinkel Academic Medical Centre, Amsterdam, The Netherlands Thursday 18 September 2014, Royal College of Physicians, London Clinical
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationHIV Virology & Resistance
Themes Viral load Tropism Drug resistance HIV Virology & Resistance Anna Maria Geretti Institute of Infection & Global Health The HIV Virology Timeline HIV-1 isolated HIV replicates at high levels throughout
More information